Interleukin-1 production by immunologically hyporeactive tumour-bearing mice
Jazyk angličtina Země Anglie, Velká Británie Médium print
Typ dokumentu časopisecké články
PubMed
2337505
PubMed Central
PMC1971620
DOI
10.1038/bjc.1990.151
Knihovny.cz E-zdroje
- MeSH
- ascitická tekutina metabolismus patologie MeSH
- experimentální sarkom imunologie metabolismus MeSH
- imunologická tolerance * MeSH
- interleukin-1 biosyntéza MeSH
- messenger RNA biosyntéza MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- nádorové buňky kultivované metabolismus MeSH
- RNA nádorová biosyntéza MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- interleukin-1 MeSH
- messenger RNA MeSH
- RNA nádorová MeSH
Mice bearing progressively growing syngeneic methylcholanthrene-induced sarcomas are immunologically hyporeactive. However, both basal (steady-state) and bacterial lipopolysaccharide (LPS)-induced synthesis of mRNA for interleukin-1 (IL-1) in peritoneal exudate cells (PEC) or spleen cells were comparable in control and tumour-bearing animals. Furthermore, the production of IL-1 by PEC stimulated with LPS in the presence of indomethacin was same in control and tumour-bearing mice. The results thus demonstrate that LPS-stimulated cells from animals bearing progressively growing syngeneic sarcomas synthesise the same quantities of mRNA for IL-1 and produce comparable amounts of IL-1 as do cells from normal animals, in spite of the profound immunological hyporeactivity of the former.
Zobrazit více v PubMed
Int J Cancer. 1978 Mar 15;21(3):348-55 PubMed
J Autoimmun. 1989 Feb;2(1):1-13 PubMed
J Immunol. 1983 Oct;131(4):1834-7 PubMed
Int J Cancer. 1983 Dec 15;32(6):733-6 PubMed
J Clin Immunol. 1983 Oct;3(4):295-315 PubMed
Cancer Immunol Immunother. 1984;16(3):182-5 PubMed
Nature. 1984 Nov 29-Dec 5;312(5993):458-62 PubMed
Cancer. 1985 Oct 1;56(7):1553-8 PubMed
Immunology. 1985 Oct;56(2):275-83 PubMed
Annu Rev Immunol. 1985;3:263-87 PubMed
J Immunol. 1985 Dec;135(6):3962-8 PubMed
Adv Cancer Res. 1985;45:1-43 PubMed
J Immunol. 1986 Apr 15;136(8):3098-102 PubMed
Cancer Res. 1986 Aug;46(8):3834-7 PubMed
J Natl Cancer Inst. 1986 Aug;77(2):425-9 PubMed
Jpn J Cancer Res. 1986 Aug;77(8):767-73 PubMed
Proc Natl Acad Sci U S A. 1987 Jun;84(11):3802-6 PubMed
Infect Immun. 1987 Sep;55(9):2061-5 PubMed
Cancer Res. 1988 Feb 1;48(3):584-8 PubMed
J Immunol. 1988 Jun 1;140(11):3830-7 PubMed
Folia Biol (Praha). 1988;34(1):42-7 PubMed
Cancer Res. 1988 Nov 1;48(21):6011-6 PubMed
Immunol Lett. 1988 Jul;18(3):213-8 PubMed
Int J Cancer. 1988 Nov 15;42(5):712-4 PubMed
Am J Med. 1988 Nov;85(5):668-74 PubMed
J Leukoc Biol. 1988 Dec;44(6):474-84 PubMed
J Exp Med. 1988 Dec 1;168(6):2031-43 PubMed
Biochemistry. 1979 Nov 27;18(24):5294-9 PubMed
